In recent trading session, Lyra Therapeutics Inc (NASDAQ:LYRA) saw 0.57 million shares changing hands at last check today with its beta currently measuring -0.06. Company’s recent per share price level of $0.17 trading at $0.0 or -1.43% at last check today assigns it a market valuation of $11.30M. That most recent trading price of LYRA’s stock is at a discount of -3894.12% from its 52-week high price of $6.79 and is indicating a premium of 5.88% from its 52-week low price of $0.16. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 1.25 million if we extend that period to 3-months.
For Lyra Therapeutics Inc (LYRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 3.00. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 2 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 0 in the current quarter.
Lyra Therapeutics Inc (NASDAQ:LYRA) trade information
Upright in the red during last session for losing -1.43%, in the last five days LYRA remained trading in the red while hitting it’s week-highest on Monday, 03/10/25 when the stock touched $0.17 price level, adding 11.04% to its value on the day. Lyra Therapeutics Inc’s shares saw a change of -16.42% in year-to-date performance and have moved -10.30% in past 5-day. Lyra Therapeutics Inc (NASDAQ:LYRA) showed a performance of -12.21% in past 30-days. Number of shares sold short was 1.88 million shares which calculate 1.99 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 0.5 to the stock, which implies a rise of 66.0% to its recent value today. Analysts have been projecting 0.5 as a low price target for the stock while placing it at a high target of 0.5. It follows that stock’s current price would drop -194.12% in reaching the projected high whereas dropping to the targeted low would mean a loss of -194.12% for stock’s current value.
Lyra Therapeutics Inc (LYRA) estimates and forecasts
This year revenue growth is estimated to fall -32.88% from the last financial year’s standing.
Company posted 532k and 598k of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -21.63% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 42.42% while estimates for its earnings growth in next 5 years are of 21.95%.
Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders
Insiders are in possession of 0.60% of company’s total shares while institution are holding 51.19 percent of that, with stock having share float percentage of 51.50%. Investors also watch the number of corporate investors in a company very closely, which is 51.19% institutions for Lyra Therapeutics Inc that are currently holding shares of the company. PERCEPTIVE ADVISORS LLC is the top institutional holder at LYRA for having 12.76 million shares of worth $3.53 million. And as of 2024-06-30, it was holding 19.4892 of the company’s outstanding shares.
The second largest institutional holder is CITADEL ADVISORS LLC, which was holding about 4.77 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.2912 of outstanding shares, having a total worth of $1.32 million.
On the other hand, iShares Russell 2000 ETF and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024, the former fund manager was holding 2.44 shares of worth $0.42 million or 3.72% of the total outstanding shares. The later fund manager was in possession of 992.54 shares on Dec 31, 2024, making its stake of worth around $0.17 million in the company or a holder of 1.52% of company’s stock.
